KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Capital Leases (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 15 years of Capital Leases data on record, last reported at $111.4 million in Q1 2025.

  • For Q1 2025, Capital Leases fell 69.18% year-over-year to $111.4 million; the TTM value through Mar 2025 reached $111.4 million, down 69.18%, while the annual FY2024 figure was $112.8 million, 70.01% down from the prior year.
  • Capital Leases reached $111.4 million in Q1 2025 per VRTX's latest filing, down from $112.8 million in the prior quarter.
  • Across five years, Capital Leases topped out at $530.3 million in Q1 2021 and bottomed at $111.4 million in Q1 2025.
  • Average Capital Leases over 5 years is $386.1 million, with a median of $417.6 million recorded in 2023.
  • Peak YoY movement for Capital Leases: grew 0.55% in 2021, then plummeted 70.79% in 2024.
  • A 5-year view of Capital Leases shows it stood at $509.8 million in 2021, then fell by 15.5% to $430.8 million in 2022, then decreased by 12.7% to $376.1 million in 2023, then plummeted by 70.01% to $112.8 million in 2024, then fell by 1.24% to $111.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Leases were $111.4 million in Q1 2025, $112.8 million in Q4 2024, and $114.0 million in Q3 2024.